Loading...
Bio-Techne Corp (TECH) is not a strong buy for a beginner, long-term investor at this moment. While there are some positive developments, such as the CE-IVD marking for the Ella platform and modest improvements in net income and EPS, the overall technical indicators, options sentiment, and hedge fund activity suggest caution. The stock's financial performance and analyst ratings are mixed, and the lack of strong trading signals further supports a hold recommendation.
The MACD is negative and contracting (-1.038), RSI is neutral at 25.485, and moving averages are converging, indicating no clear trend. The stock is trading near its key support level (S1: 58.432), with resistance levels at R1: 66.989 and R2: 69.632. Overall, the technical indicators suggest a lack of strong upward momentum.

The Ella platform's CE-IVD marking for clinical use in the EU enhances market access and application in precision diagnostics. Analysts have raised price targets recently, with some maintaining a Buy rating. Net income and EPS have shown YoY growth.
Hedge funds are aggressively selling, with a 5004.01% increase in selling activity over the last quarter. Revenue and gross margin have declined YoY. The MACD and RSI do not indicate bullish momentum, and options data reflects bearish sentiment. Insiders are neutral, and there is no recent congress trading activity.
In Q2 2026, revenue slightly dropped by -0.39% YoY to $295.88M, while net income increased by 8.93% YoY to $38.00M. EPS also rose by 9.09% YoY to $0.24. However, gross margin decreased by -1.43% YoY to 65.29%. The financials show mixed performance, with modest improvements in profitability but a decline in revenue and gross margin.
Analysts have raised price targets recently, with targets ranging from $65 to $80. Some firms maintain a Buy rating, while others hold a Neutral or In Line rating. The sentiment is mixed, with cautious optimism about future growth but concerns about near-term headwinds and flat growth in the mid-year.